跳到正文
原文
Regulatory Affairs Professionals Society· @RAPSorg · X·· 2026-10-17精选AI 评分58
AI 导读

FDA 已向多家药品生产企业发出警告信,原因是未达到现行药品生产质量管理规范(cGMP)要求;同时向一家研究实验室发出警告信,原因是未遵守药物非临床研究质量管理规范(GLP)。

推荐理由

FDA 向多家药企发出 cGMP 警告信并首次涉及 GLP 违规,可观察其检查关注点的分布。

正文

FDA has issued warning letters to several drug manufacturers for failing to meet current good manufacturing practices requirements, and to a research laboratory for failing to comply with good laboratory practices.

https://hubs.la/Q04BnFgM0

来源:Regulatory Affairs Professionals Society · x.com